Skip to main
LIVN

Livanova (LIVN) Stock Forecast & Price Target

Livanova (LIVN) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

LivaNova has demonstrated robust growth, with sales increasing by 29% to $803 million in 2024, and management anticipates further revenue growth, projecting sales between $940 million and $955 million for the upcoming year. The company's strategic focus on key markets, with approximately half of its revenue generated in the US and an additional 21% from Europe, positions it favorably within the global medical device sector. Additionally, the potential market share expansion of its aura6000 product, with projections indicating sales could rise substantially from $30 million in 2027 to $280 million by 2029 under favorable conditions, underscores a positive trajectory for future performance.

Bears say

LivaNova faces significant challenges that contribute to a negative outlook on its stock, including anticipated revenue growth slowing to low-single digits, primarily due to ongoing headwinds in its Neuromodulation and Cardiovascular businesses. Additionally, there are concerns about operating margin contraction and the potential for below-consensus earnings, which could further strain the company's financial performance. Risks associated with regulatory approvals, particularly for the aura6000 device, along with slower growth in key segments, exacerbate the uncertainty surrounding LivaNova's future profitability and market position.

Livanova (LIVN) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Livanova (LIVN) Forecast

Analysts have given Livanova (LIVN) a Buy based on their latest research and market trends.

According to 8 analysts, Livanova (LIVN) has a Buy consensus rating as of Jan 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $65, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $65, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Livanova (LIVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.